The Pharmaceutical Manufacturing Group of the Manufacturers Association of Nigeria (PMG-MAN) is preparing to host its upcoming Nigeria Pharma Manufacturers Expo, an event that serves as a focal point for the country’s industrial aspirations in the life sciences sector. As the executive secretary of the organization, Pharm. Frank Mounemeh, emphasizes, the event is more than a trade show; it is a strategic platform designed to bridge the gap between national health security and industrial self-sufficiency. With the Nigerian pharmaceutical market projected to continue its upward trajectory, the urgency to localize production has never been more critical.

The Strategic Importance of the Nigeria Pharma Manufacturers Expo

The upcoming Expo is positioned to host nearly 200 international and domestic companies, with an anticipated attendance of up to 4,000 stakeholders. This gathering is essential in a landscape where Nigeria remains heavily reliant on imported finished pharmaceutical products and raw materials, particularly Active Pharmaceutical Ingredients (APIs). By inviting exhibitors from major manufacturing hubs such as India, China, and various European nations, the organizers aim to facilitate a technology transfer that is vital for the growth of local production facilities.

Historically, the Nigerian pharmaceutical sector has struggled with high dependency on imports. The Expo seeks to reverse this by showcasing advanced machinery, clean-room technology, and laboratory equipment necessary for modern, high-quality production. For young professionals and entrepreneurs, the event offers a gateway into a sector often perceived as capital-intensive and inaccessible. Through technical sessions and mentorship from established industry leaders, the Expo aims to demystify the manufacturing process and provide a roadmap for the next generation of pharmacists and engineers to enter the value chain.

Chronology of Policy Interventions and Industrial Evolution

The push for local manufacturing in Nigeria did not occur in a vacuum. It is the result of a series of deliberate, if sometimes inconsistent, policy measures implemented over the last decade.

• 2019-2020: NAFDAC intensifies the implementation of the "5+5" policy. This mandate requires companies that have held product marketing authorizations for five years to transition to local manufacturing within another five-year window, or face the loss of their registration status.
• 2021-2023: The Nigerian government introduces various presidential executive orders aimed at incentivizing local production, including the provision of a 7.5% incentive on imported inputs to lower the cost of production.
• 2024-2025: The industry experiences a shift following the exit of several major multinational pharmaceutical companies. While some observers viewed this as a loss, local manufacturers rapidly filled the vacuum, particularly in the production of beta-lactam antibiotics and essential therapeutic drugs.
• 2026 (Present): The sector is now focused on "regional sovereignty," aiming to leverage the African Continental Free Trade Area (AfCFTA) to turn Nigeria into a continental manufacturing powerhouse.

Data-Driven Analysis of the Current Landscape

The need for localization is underscored by alarming health-economic data. With over 130 million Nigerians currently living in multidimensional poverty, the reliance on out-of-pocket expenditure—which accounts for roughly 70% to 76% of total healthcare spending—is unsustainable. High costs are exacerbated by the reliance on imports, which are vulnerable to foreign exchange fluctuations and global supply chain disruptions.

Furthermore, the cost of production in Nigeria is significantly inflated by energy requirements. While manufacturers in competing nations like China face energy costs that account for less than 5% of production expenses, Nigerian firms often allocate up to 40% of their operational budget to power generation. This energy deficit is a primary driver of the high retail prices for medicines, creating a paradox where life-saving drugs are frequently priced beyond the reach of the average citizen.

Official Responses and the Challenge of Execution

The consensus among industry leaders is that the policy framework in Nigeria is strong, but the execution remains flawed. The "5+5" policy, spearheaded by the National Agency for Food and Drug Administration and Control (NAFDAC), is widely regarded as a success story in shifting corporate behavior. It has compelled long-term importers to invest in domestic infrastructure, thereby increasing the count of local manufacturing facilities.

However, the implementation of presidential executive orders has faced bureaucratic hurdles. For instance, the 7.5% fiscal incentive for machinery and API imports faced delays in institutionalizing an implementation framework, limiting its immediate impact. Moreover, systemic issues at the ports—such as the inefficient transition from the B-Odogwu platform to the National Single Window—continue to cause delays, increase demurrage, and drive up the final cost of pharmaceutical products.

Regional Aspirations and the AfCFTA

Nigeria’s potential as a pharmaceutical hub for West and Central Africa is immense. As the largest economy in the region, Nigeria is uniquely positioned to lead the transition toward African pharmaceutical sovereignty. By strengthening the domestic value chain—from R&D and raw material processing to finished dosage forms—Nigeria can move from being a net importer to a significant regional exporter.

The African Continental Free Trade Area (AfCFTA) provides the structural framework for this expansion. By reducing trade barriers, the agreement allows Nigerian manufacturers to scale production to serve a larger, pan-African market. This shift is not merely about production volume; it is about building a sustainable ecosystem that includes contract research organizations (CROs) and bioequivalence testing facilities, which are essential for the production of biosimilars and high-end generics.

The Path Forward: Policy Consistency and Execution

The fundamental challenge for the Nigerian pharmaceutical sector, as identified by PMG-MAN leadership, is the "90/10" rule of policy: 10% design and 90% execution. While the government has demonstrated a willingness to support the industry through fiscal policies and regulatory mandates, the success of these initiatives is often hampered by the lack of continuity.

To achieve long-term medicine security, the government must prioritize:

1. Policy Stability: Extending the current presidential executive orders for at least another two years to allow for market stabilization and to provide manufacturers with the predictability required for long-term capital investment.
2. Infrastructure Integration: Addressing the energy crisis by providing subsidized power or dedicated industrial zones for pharmaceutical manufacturers to lower the high cost of production.
3. Regulatory Efficiency: Eliminating the bottlenecks at the ports and simplifying the customs process for pharmaceutical inputs to ensure that raw materials are cleared and moved into production cycles without delay.
4. Capacity Building: Investing in the workforce by promoting specialized training in pharmaceutical engineering, quality assurance, and regulatory affairs, ensuring that the local industry has the technical expertise to compete globally.

The goal of creating a self-sufficient pharmaceutical sector is not just an industrial objective; it is a public health necessity. As the Nigeria Pharma Manufacturers Expo approaches, the industry is signaling that it is ready to take the next step. Whether the sector achieves its potential will depend on the government’s ability to move beyond rhetoric and provide a consistent, executable, and supportive policy environment that empowers local manufacturers to meet the healthcare needs of the nation and the continent.